GUIDA UPG2 (versione del 16-1-06) 1

PROGETTO LEONARDO UNIPHARMA-GRADUATES

leonardopharma@uniroma1.it

(versione del 15/12/05)

GUIDA UPG2 (versione del 16-1-06) 2

SOMMARIO

UNITED KINGDOM (REGNO UNITO) ................................................................................................................................. 3 GlaxoSmithKline (HARLOW) .............................................................................................................................................. 3 NEUTEC PHARMA PLC (MANCHESTER) ........................................................................................................................ 3 CYPROTEX (MANCHESTER)............................................................................................................................................. 4 UNILEVER (PORT SUNLIGHT, LIVERPOOL) .................................................................................................................. 4 NEWCHEM TECHNOLOGIES LTD (NEWCASTLE-UPON-TYNE) .................................................................................. 5 INSTITUTE OF FOOD RESEARCH (NORWICH).............................................................................................................. 5

DEUTSCHLAND (GERMANIA) ............................................................................................................................................ 6 MAX PLANCK INSTITUT FOR MOLECULAR GENETICS (BERLIN).............................................................................. 6 SANOFI-AVENTIS (FRANKFURT)..................................................................................................................................... 6 COLEY PHARMACEUTICAL (LANGENFELD)................................................................................................................. 7 BAYER CROPSCIENCE (MONHEIM)................................................................................................................................ 8 FRAUNHOFER INSTITUTE OF TOXICOLOGY AND EXPERIMENTAL MEDICINE (HANNOVER)............................. 8 FORSCHUNGSZENTRUM KARLSRUHE........................................................................................................................... 8 INSTITUTE OF ENVIRONMENTAL RESEARCH (AACHEN) ........................................................................................... 9 UFZ – Centre for Environmental Research Leipzig – Halle (LEIPZIG) ........................................................................... 10 FRAUNHOFER INSTITUTE – FIRST (BERLIN) .............................................................................................................. 10 DEPARTMENT FOR DEVELOPMENTAL BIOLOGY (ESSEN)...................................................................................... 11 BAXTER BIOSCIENCE (WIEN) ........................................................................................................................................ 11 JOANNEUM RESEARCH ForschungsGmbH (GRAZ) ...................................................................................................... 11

NEDERLAND (OLANDA).................................................................................................................................................... 12 ORGANON (EINDHOVEN)............................................................................................................................................... 12 UNILEVER FOODS RESEARCH CENTRE (VLAARDINGEN) (Rotterdam).................................................................... 13 CELL BIOLOGY & IMMUNOLOGY (WAGENINGEN) ................................................................................................... 13 PLANT RESEARCH INTERNATIONAL (WAGENINGEN).............................................................................................. 14 Philips Electronics Nederland b.v. (EINDHOVEN)........................................................................................................... 14

DANMARK (DANIMARCA)................................................................................................................................................ 14 LEO PHARMA (COPENHAGEN) ..................................................................................................................................... 14

SVERIGE (SVEZIA).............................................................................................................................................................. 15 KAROLINSKA INSTITUTET (STOCKHOLM) .................................................................................................................. 15 PROTISTA (Copenhagen).................................................................................................................................................. 15

BELGIUM (BELGIO) ............................................................................................................................................................ 16 REALCO (Brussels) ........................................................................................................................................................... 16

FRANCE (FRANCIA) .............................................................................................................................................................. 17 INSTITUT DE RECHERCHE PIERRE FABRE (CASTRES) ............................................................................................. 17 INSTITUT CURIE (PARIS)................................................................................................................................................ 17 CARSO (LYON).................................................................................................................................................................. 18 HUMPROTHER LABORATORY (Grenoble)..................................................................................................................... 18 INSTITUT DE BIOLOGIE ET CHIMIE DES PROTEINES (CNRS-IBCP) LYON ............................................................ 19 DIFFERENTIATION & CELL CYCLE GROUP, ECOLE NORMALE SUPERIEURE DE LYON.................................... 19

IRLANDA .............................................................................................................................................................................. 20 PR euroCHEM Ltd (CORK)............................................................................................................................................... 20

SPAGNA ................................................................................................................................................................................ 20 NEUROPHARMA (MADRID)............................................................................................................................................ 20

GUIDA UPG2 (versione del 16-1-06) 3UNITED KINGDOM (REGNO UNITO)

GlaxoSmithKline (HARLOW)

New Frontiers Science Park 3rd Avenue,

Harlow, Essex, CM19 5AW Website: http://www.gsk.com/index.htm

(25 miles from London) Brief description of the Centre GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infective, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. Based on 2002 Annual Results, GSK had sales of £21.2 billion ($31.8 billion) and profit before tax of £6.5 billion ($9.7 billion). Pharmaceutical sales accounted for £18 billion ($27 billion) with new products representing 27% of total pharmaceuticals sales. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Over 42,000 employees work at 91 manufacturing sites in 38 countries and over 16,000 are in R&D. GSK R&D is based at 24 sites in seven countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.4bn/$4bn.

NEUTEC PHARMA PLC (MANCHESTER)

NeuTec Pharma Plc 2nd Floor Clinical Sciences Building

Manchester Royal Infirmary Oxford Road

Manchester, M21 7LT Website: www.neutecpharma.com

Brief description of the Research Centre NeuTec Pharma is a small biotech company focusing on the development of new protein based anti-microbial therapeutics. We develop molecules based on antibodies from patients recovering from infection. Some of these antibodies are protective and it is the job of the research labs to identify these antibodies and make genetically engineered versions. The first product, Mycograb, has successfully completed Phase III trails and is awaiting market authorization. The second product, Aurograb, is in the last stage of clinical trials. NeuTec Pharma developed from the University of Manchester, Department of Medical Microbiology in 1997. It is still based within university labs on the site of the Central Manchester Teaching Hospital. With close connections to the Clinical Microbiology Service (NHS).

GUIDA UPG2 (versione del 16-1-06) 4 The research laboratories focus primarily on DNA and protein based molecular biology techniques. Labs are well stocked with equipment for many of the most up-to-date techniques including :- DNA sequencing DNA cloning Recombinant protein expression and purification Proteomics Protein sequencing Microbiology Immunology Pharmacokinetics and pharmacodynamics The Labs are based in the centre of the university district, 15 minute walk from the city centre.

CYPROTEX (MANCHESTER)

Cyprotex Discovery Limited 15 Beech Lane

Macclesfield, Cheshire SK10 2DR Website: http://www.cyprotex.com/

(30 km South of Manchester)

Cyprotex PLC is a small (30 people) company specialising in developing Predictive screening and software for estimating pharmacokinetic behaviour of novel compounds produced by drug discovery companies. Cyprotex was formed as a public company in 2001 and has so far developed 2 key technologies, Cloe Screen™, which is a high throughput screening facility for ADMET1 properties; and Cloe PK™ which is software for simulation of pharmacokinetics in humans and other animals. Cyprotex has contracts with multiple Pharmaceutical companies, including AstraZeneca and Roche and has recently raised €6m from institutional investors which provides financial stability for the foreseeable future. We are now actively extending our Cloe™ technology into chemical structure design, structure-based predictive tools for ADMET, virtual screening and other areas and have a number of training opportunities for graduates that should meet the criteria of the scheme. The graduates would join a team comprising experienced software engineers and scientific computing experts and contribute directly to knowledge development in support of our research.

UNILEVER (PORT SUNLIGHT, LIVERPOOL)

Unilever Research and Development Port Sunlight Quarry Road East

Bebington Wirral CH63 3JW

Website: www.unilever.com (15Km from Liverpool)

Brief description of the Research Centre Unilever is one of the world’s most successful consumer good companies; dedicated to meeting the everyday needs of people everywhere. Globally, a quarter of a million people work to generate a turnover of Euro 42.0 billion (2003). Our foods and home and personal care brands reach consumers in all corners of the globe

1 Absorption, Distribution, Metabolism and Elimination and Toxicology

GUIDA UPG2 (versione del 16-1-06) 5helping people feel good, look good and get more out of life. In fact someone, somewhere reaches for a Unilever product 150 million times a day. Unilever R&D Port Sunlight: Globally Unilever invests approximately 2.5% of its turnover in research and development each year, and is the UK’s fourth biggest investor. This investment is a measure of Unilever’s commitment to science and technology and the pivotal role that science and technology plays in Unilever’s competitive edge. Every product Unilever makes and sells results from the application of science. Unilever’s scientists enjoy the best of both worlds – being at the cutting edge of technology and also seeing their innovations deliver practical results every day to the consumer. Unilever R&D Port Sunlight is the leading site for research and development into the companies home and personal care brands. Over 850 scientists work to combine understanding in areas such as material, physical, biological, and process sciences with the best consumer insight to give innovative branded products ready to be sold on the world’s supermarket shelves. The global brands our scientists innovate for include Dove, Sunsilk, Lynx, Cif, Omo, Mentadent and Comfort.

NEWCHEM TECHNOLOGIES LTD (NEWCASTLE-UPON-TYNE)

Newchem Technologies Ltd. Holly Lodge

Whitesmocks, Durham, DH1 4LH Website: www.newchemtechnologies.com

(30 Km from Newcastle-Upon-Tyne) Brief description of the Research Centre NewChem Technologies works collaboratively with the School of Natural Sciences and also the School of Chemical Engineering (RAE grade 5 UoA) and Advanced Materials at the University of Newcastle. All research trainees are allocated space in appropriate laboratories and have suitable office accommodation, with desk and storage space as well as telephone access. The Schools maintain a modern network facility equipped with Microsoft Office, MATLAB, MINITAB, and other specialised software for all its trainees. Schools also provide lab-books, printing facilities and photocopiers. Trainees also have access to telephone, fax and multi-colour printer services. In addition, the trainees will have free access to the well stocked University library, which maintains comprehensive subscriptions to all field-leading print and electronic journals.

INSTITUTE OF FOOD RESEARCH (NORWICH)

Norwich research park, Colney, Norwich Website: www.ifr.ac.uk

Brief description of the Research Centre

The Institute of Food Research (IFR) is a not-for-profit company with charitable status. It is sponsored by the Biotechnology & Biological Sciences Research Council. IFR is the UK’s only integrated basic science provider focused on food. Our research is concerned with the safety and quality of food, and improving diet and health in people.

Our scientific research collaboration stretches across the world through informal and formal partnerships. Outcomes feed into national and international strategies, delivering advice and solutions for UK Government, public sector bodies, regulatory authorities, industry and consumers. Full details of our science can be viewed at: http://www.ifr.ac.uk/science/

GUIDA UPG2 (versione del 16-1-06) 6 DEUTSCHLAND (GERMANIA)

MAX PLANCK INSTITUT FOR MOLECULAR GENETICS (BERLIN)

Max-Planck-Institute for Molecular Genetics Ihnestrasse 63-73,

D-12157 Berlin Website: http://www.molgen.mpg.de

(15 km from City Centre)

Brief description of the Research Center The Max-Planck-Institute for Molecular Genetics, which consists of 3 departments and is home to over 410 researchers, technicians, graduates and administrative staff. Within the International Max-Planck Research School (IMPRS-CBSC) additional graduates are supervised. The institute regularly hosts workshops, conferences and summer schools on networks and molecular interactions. Currently a new biocomputing-cluster is being installed in the research group. Through the institutes’ IT infrastructure we have access to up to 200 computing nodes on demand for complex calculations. In addition, a dedicated high-end graphics-workstation is readily available in the lab for the 2D and 3D visualisation of large-scale protein interaction networks, protein interfaces and protein structures. Bioinformatics / Structural Proteomics Computational approaches to interaction networks http://www.imprs-cbsc.mpg.de/faculty/lappe.shtml Selected Publications : - Lappe, M. and L. Holm (2004). "Unraveling protein interaction networks with near-optimal efficiency." Nat Biotechnol 22(1): 98-103. - Hermjakob, H., L. Montecchi-Palazzi, et al. (2004). "The HUPO PSI's Molecular Interaction format—a community standard for the representation of protein interaction data." Nat Biotechnol 22(2): 177-183. - Lappe, M., J. Park, et al. (2001). "Generating protein interaction maps from incomplete data: application to fold assignment." Bioinformatics 17 Suppl 1: S149-56.

SANOFI-AVENTIS (FRANKFURT)

Aventis Pharma Deutschland GmbH Industriepark Höchst

HR Recruitment & Marketing Gebäude D 706

D-65926 Frankfurt am Main Website: http://www.aventis.com/main/page.asp

Research centre: Frankfurt am Main Aventis is a world leader in the discovery, development and marketing of innovative pharmaceutical products and human vaccines. Working in a network with partners, Aventis scientists are discovering and developing therapeutic innovations in areas such as cancer, diabetes, cardiovascular disease, asthma and allergies. Our goal is to satisfy unmet medical needs. Our vision is to create and sustain value by being recognized as a pharmaceutical industry leader – valued by patients and healthcare providers, sought after as an employer and respected by the scientific community and by our competitors. Aventis is the number one pharmaceutical company in Germany. Major Aventis activities in Germany encompass research and development to industrial

GUIDA UPG2 (versione del 16-1-06) 7operations and marketing. Aventis Germany is one of the top employers in the pharmaceutical industry in Germany (7500 employees in 2002), but also is the top producer and exporter of medicines and one of the largest investor in R&D (500 Mio € R&D budget spent in Germany in 2002). At Aventis, R&D has moved well beyond the traditional boundaries. Our Drug Innovation & Approval (DI&A) organization has adopted a network-centric approach, and replaced sequentially functioning silos of research and development with a network of sites, centres of expertise and global functions. Multifunctional project teams form the core units of innovation, while centres of expertise provide the best technical and scientific support to the projects. This networked approach helps to extract maximum value from the tremendous amounts of data generated by genomics and new technologies. Drug discovery is located at three strategic sites in the United States, France and Germany. These sites are responsible for moving projects from exploratory through early clinical stages, and operate entrepreneurially in a biotech-style environment. To reach their goal of managing their assigned portfolio of drug candidates through phase IIa, DI&A sites are assisted by the following global functions: Generation works with the disease groups to discover innovative new targets, leads and candidates for clinical development. They provide genomics technologies for target validation, high-throughput technologies for screening and chemistry for state of the art lead identification and compound optimisation. Optimisation bridges the traditional gap between drug discovery and development. They are responsible for leading the selection of new compounds and the transfer of selected compounds to late-stage development. A key role of the Lead Optimisation function is to help ensure that only candidates with the greatest chance of success are selected for phase IIb and III studies. Development, including regulatory processes, are coordinated by the Global Drug Development Centre in Bridgewater, New Jersey, USA. Regional development centres are located in Paris, Bridgewater and Tokyo. This network optimises the conduct of clinical trials, facilitates global submissions, and maximizes product life-cycle management. The network is comprised of the following global functions: Product Realization manages late-stage (phase IIb and III) clinical studies worldwide and optimises the value of strategic brands by delivering additional dosage forms and new therapeutic indications. Global Regulatory Approvals & Marketing Support (GRAMS) brings drug candidates through the regulatory approval process and helps keep them on the market. They direct the simultaneous submission of new compounds in major markets, and serve as the company’s primary interface with regulatory bodies and government agencies. Aventis DI&A Germany In Germany more than 1,300 scientists including biologists, chemists, pharmacologists, toxicologists, pharmacists and physicians are all working together towards the discovery of new treatments for diabetes, cardiovascular diseases, thrombosis and osteoarthritis.

COLEY PHARMACEUTICAL (LANGENFELD)

Coley Pharmaceutical Elisabeth Selbert Str. 9

D-40764 Langenfeld Website: http://www.coleypharma.com/index_flat.html

(30 Km between Düsseldorf and Cologne) Research Centre: Langenfeld Coley Pharmaceutical Group discovers, develops and commercializes a new class of drugs that stimulate the human immune system to treat and prevent cancer, asthma, allergy and infectious diseases. Based on proprietary CpG oligonucleotides, or CpG oligos, a family of molecules that were discovered to mimic the immunostimulatory properties of bacterial DNA, Coley's products activate innate and adaptive immune responses to fight disease. The company's lead product, CpG 7909 (PROMUNE®), is currently in Phase II clinical trials both as a monotherapy drug and as part of combination therapy to treat various types of cancer. Additional Phase I/II clinical trials are ongoing in infectious disease, as well as vaccine efficacy trials. Coley is a private company with Executive Offices in the United States and Research and Development Operations in Langenfeld, Germany and Ottawa, Canada. At Coley’s center for basic research in Germany, a novel Human Cell Screening (HCS) discovery platform has been established which allows for the rapid development and

GUIDA UPG2 (versione del 16-1-06) 8validation of new product candidates. In addition, the chemical synthesis of novel oligonucleotide derivatives, their purification and analytical characterization, are core activities of the German Operations. The Coley Site in Germany, where the graduate will be working, is located in Langenfeld. Langenfeld, a pleasant town on the Rhine situated between the cities Düsseldorf and Cologne, can easily be reached by public transportation.

BAYER CROPSCIENCE (MONHEIM)

Bayer CropScience AG Global Biology Insecticides,

Building 6220, Alfred Nobel Str.50, D-40764 Monheim

Website: http://www.bayercropscience.com (Cologne/Düsseldorf 20km)

Brief description of the Research Center Research Biology Fungicides is a department within Research of the agrochemical/crop protection company BAYER CROPSCIENCE AG. The group interested to join the program is working in the field of Fungicide systemicity and physiology, diagnostics and resistance. We are doing research on the systemicity of compounds, Fusarium head blight and other cereal diseases and mechanisms of resistance of active ingredients used to control fungal growth. The laboratory is well equipped with state-of-the-art technologies (biology, biochemistry and molecular biology) and is actively involved in cutting-edge research especially in the field of fungicidal action and resistance. FRAUNHOFER INSTITUTE OF TOXICOLOGY AND EXPERIMENTAL MEDICINE (HANNOVER)

Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM) Department Drug Research and Medical Biotechnology

Nikolai-Fuchs-Str. 1, D-30625 Hannover

Website: www.item.fraunhofer.de

Brief description of the Research Center At the Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM), expertise in various disciplines in toxicology, human and veterinary medicine, biology, biochemistry, chemistry and physics forms the basis for comprehensive research work and services, including drug research, consumer and environmental protection. The activities of the department Drug Research and Medical Biotechnology are focused on preclinical studies for the chemical and pharmaceutical industry. The object is to detect causal relationships between dose and effect of pharmaceuticals. In addition to molecular-biological methods, numerous pharmacological in vivo and in vitro methods are available for investigating molecular mechanisms at molecular, cell or organ levels and in animal models.

FORSCHUNGSZENTRUM KARLSRUHE

Herrmann-Helmholtz Platz 1 D-76634 Eggenstein-Leopoldshafen

GUIDA UPG2 (versione del 16-1-06) 9Website: www.fzk.de/biostruct

(12 km from Karlsruhe, 40 km from Mannheim, 50 km from Heidelberg)

The research center Karlsruhe is one of Germany’s premier National Laboratories, presently, employing over 3500 people in many different scientific fields. It basic mission is to develop and provide the infrastracture for challenging scientific problems facing the German society. Through cooperation with German universities, the Research Center Karlsruhe support vigorous Ph.D. programmes in a variety of scientific disciplines. The Institute for Nanotechnology (INT) is one of the premier research centers in Germany focusing on the development of a wide array of key technologies for the development of nanotechnology. The biomolecular simulation group at the INT focuses on the development of computational tools for de-novo protein folding and in-silico drug design. We have developed forcefields and simulation methods that permit all-atom protein folding for small proteins on the basis of the amino acid sequence. We have also developed FlexScreen, a tool for high-throughput in-silico screening for rational drug design. Please consult our website: www.fzk.de/biostruct for additional information.

INSTITUTE OF ENVIRONMENTAL RESEARCH (AACHEN)

Institute Of Environmental Research-Chair for Environmental Biology and Chemodynamics

Aachen University Worringerweg 1

D-52074 Aachen (Aquisgrana) Website: www.bio5.rwth-aachen.de

Brief description of the Research Center The Institute of Environmental Research (Chair of Environmental Biology and Chemodynamics) of the RWTH Aachen University comprises projects on the ecology of terrestrial biocoenoses and their utilisation for bioindication as well as research activities on the environmental fate and behaviour of chemicals, on the remediation of contaminated sites and on novel analytical measurement methods. Starting point of our work are the environmental burdens resulting from a variety of chemical compounds, e.g. pesticides, endocrine disrupting industrial chemicals, and toxic heavy metals. Our research activities aim at increasing the knowledge on fate and effects of these substances in the environment – particularly in soil, water, and plants – and at the development of methods that allow assessment, remediation or even complete avoidance of these burdens. The RWTH Aachen is connected by a cooperation contract with the Fraunhofer-Institute for Molecular Biology and Applied Ecology (IME) in Schmallenberg. Prof. Schäffer is head of IME's Applied Ecology division. The goal of the research and development projects of IME is to recognise and assess chances and risks of synthetic and biogenic compounds for consumers and environment as well as to develop and realise strategies for their protection. In 2003 the RWTH Aachen associated research institute for ecosystem analysis and assessment e.V. gaiac („Aninstitut“ of RWTH Aachen) was founded with Prof. Schäffer as chairman of the board. The research aim of the institute located in Aachen is to analyse and assess anthropogenic influences and stressors in terrestric and aquatic ecosystems. It has beside offices many laboratories for research and education practical training. Among them special facilities such as L1 and L2 laboratories as well as isotopic laboratories for the work with radioactive compounds are available. Temperature-controlled chambers, and green houses as well as indoor microcosms, and outdoor terrestrial and aquatic mesocosms, and fish aquariums are available for ecotoxicological studies. For ecochemical work, the necessary radio-analytical (LSC, sample oxidiser, radiodectors (solid and liquid) for HPLC and bioimager for TLC) and analytical equipment (TLC, 2 HPLC and HPSEC with fluorescence detector and DAD, 3 GC-MS, 2 GC-FID, 3 GC-ECD, 2 AAS), including a microwave extractor is available. For microbiology and molecular biology works climatised chambers are available with shakers, thermocyclers, sequencers, electrophoreses equipment, and multi-purpose system for DGGE, TGGE and SSCP. Furthermore, the chair possesses different bioreactors (MBR, fermenter, fixed-bed reactor) and phytobox for experiments with plants in defined atmosphere.

GUIDA UPG2 (versione del 16-1-06) 10

UFZ – CENTRE FOR ENVIRONMENTAL RESEARCH LEIPZIG – HALLE (LEIPZIG)

UFZ – Centre for Environmental Research Stab PuN

Permoserstrasse 15, D-04318 Leipzig

Website: www.ufz.de Brief description of the Research Center

The UFZ, Centre for Environmental Research, Germany, was established in 1991 as the first and only centre in the Helmholtz Association of National Research Centres (HGF) to be exclusively devoted to environmental research in a great variety of fields. It currently employs around 700 people. Founded in response to the severe pollution prevailing in Central Germany, the UFZ has already become a world-wide acknowledged centre of expertise in the remediation and renaturation of contaminated landscapes, as well as the preservation of natural landscapes. Since its foundation in 1991 the UFZ has participated in 80 EU-projects, co-ordinating 35 of them. Within the Fifth Framework Programme the UFZ has launched 22 projects co-ordinating 7 of them. In Framework six UFZ is up to now involved in 21 projects co-ordinating two Integrated Projects, one STREP, one EST, and two TOK.

FRAUNHOFER INSTITUTE – FIRST (BERLIN)

Fraunhofer Institute Kekuléstrasse 7, D-12489 Berlin

Website: http://ida.first.fraunhofer.de (Inside Berlin city limits)

Brief description of the Research Center The Fraunhofer organization, conducts applied research in close co-operation with academia and industry. The Intelligent Data Analysis (IDA) research group (35 members: 1 Full Professor, 2 tenured senior researchers, 8 PostDocs, 13 researchers and 11 graduates) of the Fraunhofer Institute for Computer Architecture and Software Technology in Berlin (FhG FIRST) is concerned with learning systems for data analysis. In particular, IDA is developing tools for high-dimensional multivariate statistics based on methods originally developed in the field of classical statistics and, more recently, in the neural networks, signal processing and machine learning community. The major objective of IDA is to pursue research all the way from theory to application. To this end, IDA is contributing to the theoretical development of new data analysis techniques, to their implementation according to software-engineering standards, and, finally, to their industrial or academic application. IDA is developing algorithms and software tools for (a) classification and regression with neural networks and support vector machines, (b) time series analysis and (c) blind source separation. Algorithms of the IDA group are used in various projects in the application fields: (1) acoustics and speech, (2) intrusion detection, (3) analysis of financial data, (4) Neuroinformatics, e.g. the analysis of (i) macroscopic neurological signals like EEG (Electro-Encephalogram), MEG/MNG (Magneto-Encephalogram, Magneto-Neurogram), (ii) microscopic data from deep brain stimulation or (iii) Human Machine Interaction in particular Brain Computer Interfacing (BCI), (5) Bioinformatics, e.g. (i) the analysis of protein structure and function, (ii) gene finding, (iii) virtual Chemistry. IDA research is therefore strongly interdisciplinary.

GUIDA UPG2 (versione del 16-1-06) 11DEPARTMENT FOR DEVELOPMENTAL BIOLOGY (ESSEN)

Centre for Medical Biotechnology

University Duisburg-Essen Universität Strasse 2

D-45117 Essen Website: www.uni-duisburg-essen.de

ÖSTERREICH (AUSTRIA)

BAXTER BIOSCIENCE (WIEN)

Baxter BioScience Industriestraße 72

A-1221 Wien Website: www.baxter.com

Brief description of the Research Center Baxter-Bioscience is one of the leading companies involved in the development and processing of therapeutic proteins both from plasma and through recombinant technology. These proteins are used to treat patients with coagulation disorders (e.g. hemophilia A and B), immune deficiencies, autoimmune diseases and other disorders that are either related to deficiencies of plasma proteins or to the host defense system. The most important therapeutic proteins include antihemophilic factors – ImmunateR (plasma - derived) and RecombinateR (recombinant); furthermore EndobulinR S/D and GammagardR (plasma-derived polyvalent immunoglobulin preparations) and TisseelR fibrin sealant. Baxter BioScience also manufactures vaccines, including the leading vaccine for tick-borne encephalitis. Graduates will work in the Department of Immunology (head: Birgit Reipert) and in the Department of Experimental Pharmacology/Transgenic Animals (head: Eva Muchitsch) at Baxter BioScience. Both departments belong to the division Global Preclinical R&D (head: Prof. Hans-Peter Schwarz).

JOANNEUM RESEARCH FORSCHUNGSGMBH (GRAZ)

Joanneum Research Forschungsgesellschaft mbH

Steyrergasse 17 A-8010 Graz

GUIDA UPG2 (versione del 16-1-06) 12Website: www.joanneum.at

Brief description of the Research Center The 14 research units make JOANNEUM RESEARCH one of the largest non-university research institutions in Austria. The role as an innovative partner for business and administration is reflected in the company’s wide range of services: apart from applied research and development for small and medium-sized enterprises JOANNEUM RESEARCH offers custom-designed technical business consulting and vast expertise in interdisciplinary management of complex research contracts at a national and international level. The JOANNEUM RESEARCH - Institute of Sustainable Techniques and Systems (JOINTS) provides the expertise required for the goal of Sustainable Development by developing sustainable production technologies based on renewable raw materials and selectively deploying ecologically efficient environmental technologies aimed to minimise pollution. The researchers of the division Chemical and Technical Plant Utilization (CTP) draw up feasibility studies from cultivation to industrial processing of plants, developing new production methods for complete use of plants, and elaborating innovative implementation strategies for the deployment of renewable raw materials. An important part of the work is to develop analytical methods and to produce extracts from plant material. NEDERLAND (OLANDA)

ORGANON (EINDHOVEN)

N.V. Organon PO Box 20,

Molenstraat 110 N-5342 CC OSS

Website: www.organon.com (55 km from Eindhoven)

Brief description of the Research Center Organon -with shared head offices in Roseland, NJ, USA, and Oss, The Netherlands- creates and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to become or remain one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary: products that contribute to the health of people and their quality of life. Organon is the human health care business unit of Akzo Nobel. Ever since our foundation in 1923 in The Netherlands we have grown into a leading research-based and market-driven company with operations throughout the world. Organon relies first and foremost on its expertise in research and development to produce breakthrough medicines. However, we have always been open to strategic alliances. At the Department of Pharmaceutics the first steps of development of a drug product are taken after development of the active substance. The active substance is formulated into a delivery form (tablet, injection, etc.), which should fulfill quality criteria with regard to biopharmaceutical aspects, technological feasibility and customer satisfaction. Both known and totally new administration concepts are developed. Furthermore, an analytical method that is able to quantify the active compound and its degradation product in the formulation / delivery form is developed and validated.

GUIDA UPG2 (versione del 16-1-06) 13UNILEVER FOODS RESEARCH CENTRE (VLAARDINGEN) (Rotterdam)

Unilever Research and Development Vlaardingen

Foods Research Centre Room A3280 PO Box 114,

3130 AC Vlaardingen Website: www.unilever.com

(10 km from Rotterdam)

Brief description of the Research Center The Foods Research Centre (FRC) is part of the Unilever Research and Development Laboratory in Vlaardingen, the Netherlands. In the FRC approx. 400 researchers are developing new concepts for food products as well as studying the interactions of food components and human health. The training position will be in the ‘Advanced Measurement and Imaging’ group. Our group supports the research process at Unilever R&D Vlaardingen with state-of-the-art analytical techniques and methods. The food research centre contributes significantly to the renewal and extension of Unilever’s product range and important products like health margarines, cholesterol lowering spreads and other food products with proven health aspects have been developed by the laboratory. In addition to the direct company output, the staff of Unilever Research Vlaardingen published yearly over 100 peer-reviewed papers in international journals.

CELL BIOLOGY & IMMUNOLOGY (WAGENINGEN)

Wageningen University Department Animal Sciences

CBI group, PO Box 338,

6700 AH Wageningen Website: http://www.zod.wau.nl/cbi

(60 km from Utrecht) Brief description of the Research Center The Cell Biology & Immunology (CBI) group at the Department of Animal Sciences of the Wageningen University is the only laboratory working on the carp immune system in Europe. The CBI group is applying specific cellular and molecular techniques in fish immunology for a further improvement of strategies in fish health control. The group is equipped with all facilities necessary for cellular and molecular immunology research. The scientist in charge, Dr. Wiegertjes has wide experience in monitoring parasite infections of carp as a model for immunological research. The CBI group combines fundamental research on the regulation of the fish immune response with strategic research on disease resistance and vaccination. The long term objective of the group is to develop fundamental knowledge for optimal health and welfare of cultured fish without affecting the environment by excessive use of antibiotics or introducing new disease problems. Central issues are the ontogeny of the immune system, the stress response and molecular characterization of molecules of key importance for genetic disease resistance. These immune factors are studied in the context of disease models, focusing on parasite-host interactions. The CBI group consists of 4 permanent scientific staff members, 6 technicians, 3 post-docs, 9 PhD graduates and some 12 MSc graduates (on an annual basis). Dr Wiegertjes has experience with Leonardo graduate placements.

GUIDA UPG2 (versione del 16-1-06) 14PLANT RESEARCH INTERNATIONAL (WAGENINGEN)

Plant Research International

Bornsesteeg 65 6708 PD, Wageningen Web site: www.plant.wur.nl

(60 km from Utrecht)

Brief description of the Research Center: Plant Research International is one of the strategic research institutes of Wageningen University and Research Centre (Wageningen UR). Wageningen UR combines fundamental and applied research with innovative education in the areas of food, agrotechnology, production systems, nature and the environment. About 5500 professionals are committed to translating technological knowledge into study programmes and practical applications. Plant Research International is a non-profit organisation that is active in all fields of plant related sciences, from molecule to agrosystems, and is the biggest Dutch research institute in the field of plant biotechnology. The total staff of about 450 persons includes members from 30 different nationalities. At any given time, some 70 researchers and trainees from abroad are playing an important role in our organisation. As all Dutch employees are at least bi-lingual, internal scientific meetings are conducted in English.

PHILIPS ELECTRONICS NEDERLAND B.V. (EINDHOVEN)

Philips Electronics Nederland B.V., Philips Research Eindhoven

High Tech Campus 5, 5656 AE Eindhoven

Website: www.research.philips.com

Brief description of the Research Center Philips Research is part of Philips Electronics N.V. Besides the main laboratory in Eindhoven, The Netherlands, there are also laboratories of Philips Research in Germany, England, Belgium, China, India and the United States (collectively some 2100 people). Our scientists work in a wide range of disciplines, from information technology, software, multimedia and digital signal processing to physics and chemistry; from mathematics to mechanics. We provide a challenging and stimulating environment, where our scientists generate options for new and improved products and processes by realizing concepts or making prototypes, in close cooperation with the Philips Product Divisions. About 1% of Philips' sales is spent on these corporate research activities. Our activities have led to the milestone of 100,000 patents, and the publishing of many thousands of technical and scientific papers. DANMARK (DANIMARCA)

LEO PHARMA (COPENHAGEN)

LEO Pharma Industriparken, 55 DK-2750 Ballerup

Website: www.leo-pharma.com

GUIDA UPG2 (versione del 16-1-06) 15(15 km outside Copenhagen)

Brief description of the Research Center LEO Pharma is a fully integrated pharmaceutical company with extensive activities ranging from research to production and sales. Our main research areas are within dermatological diseases, inflammation and cancer. Altogether 500 people are involved in our research and development. About 150 of them work with basic research within Medicinal chemistry, Biology, Biochemistry, Pharmacology Toxicology etc..Our main research site is in Ballerup outside Copenhagen, Denmark, where we have state of the art research facilities. For further information see www.leo-pharma.com SVERIGE (SVEZIA)

KAROLINSKA INSTITUTET (STOCKHOLM)

Karolinska Institutet Södersjukhuset, Department of Medicine

SE-118 83 Stockholm Website: http://www.ki.se/sos/

Brief description of the Research Center Karolinska Institutet is one of Europe’s largest medical universities. It is also Sweden’s largest medical university accounting for 30% of medical education and 40% of academic medical research in the country. It offers 19 different education programs and a number of continuing education and free courses. Research at the Karolinska Institutet ranges from basic researches at cell and molecular level through clinical research and research in nursing. About 2.4 Swedish crowns is spent per year for research at the Karolinska Institute. Karolinska Institute is known among others for its role in the award to Nobel Prize. Of the Eight Swedish Nobel laureates, five comes from the Karolinska Institute.

PROTISTA (Copenhagen)

Protista Biotechnology AB IDEON

SE-223 70 Lund Website: www.protista.se

(60 Km from Copenhagen)

GUIDA UPG2 (versione del 16-1-06) 16

BELGIUM (BELGIO)

REALCO (Brussels)

15 Av Albert Einstein B-1348 Louvain-La-Neuve

Website: www.realco.be (30 km from Brussels)

Brief description of the Center REALCO, a SME company located in the Scientific Park of Louvain-La-Neuve (Belgium), has been involved both in the production of detergents and in the wastewater treatment for 30 years. Since 12 years, REALCO became specialized in environmental biotechnology by manufacturing enzymes and/or bacterial products As a result of many years of work, the Company has developed a new concept, “The Method”, consisting in: The use of enzymes for cleaning; these biocatalysts transform organic matters into residues becoming soluble in water, instead of just removing them as it is the case for chemical detergents; The use of the synergy between enzymes and bacteria for the wastewater treatment: enzymes hydrolyze and bacteria further degrade organic residues. Enzyme is a key vector between cleaning and waste water treatment. The main markets are 1.- END USER: A range of 60 products covering the need of household duties. Speciality: biotechnology products ( enzymes and bacteria / enzymes) proved to be effective and positive for environment. - Patents: 3 patents protect 3 main innovations in that field. 2.- INSTITUTIONAL (hospital, school, factory...):

GUIDA UPG2 (versione del 16-1-06) 17A range of 130 products covering the need of institutionals in the household of sanitary, kitchen, waste water treatments and the general maintenance. - Speciality: Enzyme and bacteria/ enzymes based products. Enzymes have the advantage to clean, hydrolyse organic matter and purify water. Realco original approach is to take care about the cleaning and the purification aspects of a process in factories, institutional... 3.- FOOD INDUSTRY: Realco has proved that enzymes can replace classical detergents advantageously. As a matter of facts, enzymes will not only remove the dirt but will also transform (hydrolyse) the dirt in a way that the purification process will start at the cleaning place. Enzymes cleaning products have others advantages : not aggressive for machinery and human being (neutral pH), work by itself... 4.- WASTE WATER TREATMENT PLANT:Improvement of the general work FRANCE (FRANCIA)

INSTITUT DE RECHERCHE PIERRE FABRE (CASTRES)

Institut Pierre Fabre Pierre Fabre Research Centrer

17 avenue Jean Moulin F-81106 Castres Cedex Website: www.crpf.net (75 km from Toulouse)

Brief description of the Research Center Since 1991, the Pierre-Fabre Research Center (CRPF) (http://www.crpf.net/english/home.htm) has focused its research efforts on 3 main axes characterized by an urgent therapeutic need: cancer, cardiovascular diseases and disorders of the central nervous system.

INSTITUT CURIE (PARIS)

INSTITUT CURIE 26 rue d’Ulm

F-75005 PARIS Website: www.curie.fr

Brief description of the Research Center Internationally renowned tumor and cell biology institute. Great research environment. See web site for details

GUIDA UPG2 (versione del 16-1-06) 18CARSO (LYON)

CARSO LSEHL

321 av. Jean Jaurès F-69362 LYON Cedex 07 Website: www.carso.fr

Brief description of the Center Our laboratory CARSO-LSEHL is specialised in analysis of different matrices such as drinking and waste water, muds, soils, sediments, food, vegetables. On these substrates we perform determination of pesticides, solvents, polycyclic hydrocarbons, dioxins. On drinking water, different physico-chemical determinations are obtained in routine (pH, turbidity, TA/TAC/TH, TOC, BOD and COD, metals, anions, etc..); For our own need we develop internal methods of analysis which must be further accredited.

HUMPROTHER LABORATORY (GRENOBLE)

HumProTher Laboratory BP 217

F-38043 Grenoble Cedex 9 Website: http://www-sante.ujf-grenoble.fr/GREPI/phoxnox/accueil.htm

Brief description of the Research Center The GREPI (Groupe de Recherche et d’Etude du Phénomène Inflammatoire) is under the administrative supervision of Joseph Fourier University (U.J.F.). The Joseph Fourier University, one’s of the country’s largest, academic, non-profit research and university organisations, has rapidly achivied the status as one of the top institutions in France for higher education and research. From its history (the first university was built in 1339), the Joseph Fourier University has always stood at the forefront of higher education and fundamental research. The Joseph Fourier University’s staff includes more than 1300 faculty members (85% Ph.D holders) and 960 administrative and support personnel. The total current campus enrollment is over 17.200 graduates including 60% in Sciences and Medicine/Pharmacy and more than 23% in Engineering sciences and technologies. Over 400 foreign graduates are hosted under international exchange programmes and 200 foreign researchers are invited each year. The Joseph Fourier University has become internationally recognized for its pioneering projects in nanobiotechnologies and bio-engineering. The university is located in an outstanding scientific environment including several European research centers such as the Laue Langevin Institute (ILL), the European Synchrotron Radiation Facility (ESRF) and the European Molecular Biology Laboratory (EMBL). The North Hospital of Grenoble (« Centre Hospitalo-Universitaire, CHU de Grenoble ») is home to one of the Joseph Fourier University’s medical laboratory, known as GREPI. The GREPI is divided into 2 departments including a clinical investigation laboratory (Enzymology laboratory) which is involved into the biochemical analysis of samples from patients and a basic research laboratory on Cellular Ageing and Inflammatory Response. The excellence and the strength of the GREPI is emphasized through the daily interactions between both departments. The Enzymology laboratory is one’s of the leading laboratory in Europe for the diagnostic of orphan human diseases such as chronic granulomatous disease (CGD) and cystic fibrosis. The research laboratory on Cellular Ageing and Inflammatory Response housed 3 research units: fundamental studies of the NADPH oxydase complex and the CGD (directed by Pr. F. Morel); cellular therapy and biotechnology (co-directed by Pr. B. Polack and Dr. B. Toussaint); clinical research on fibrosis and metalloproteinases (directed by Pr. P. Gaudin). The GREPI’s staff includes more than 5 professors, 3 postdoctoral fellows, 9 Ph. D graduates (including 2 chinese), 3 laboratory technicians, 3 undergraduates graduates and 2 administrative and

GUIDA UPG2 (versione del 16-1-06) 19support personnel. Rather than isolating faculty members and research domains into separate and distincts fields, Pr. F. Morel, the director of the GREPI, has encouraged and stimulated a collaborative spirit. While the level of scientific investigation is intense, the atmosphere is collegial and technicians, graduates graduates and administrative staff all are considered part of the team to serve the best interests of research and clinical studies. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. Consequently, the GREPI scientists have currently contributed to more than 20 scientific publications to the medical literature these last 4 years.

INSTITUT DE BIOLOGIE ET CHIMIE DES PROTEINES (CNRS-IBCP) LYON

7, Passage du Vercors F-69367 Lyon Cedex 07

Website: http://www.ibcp.fr/fr/index.php Brief description of the Research Center The Institute of Protein Biology and Chemistry (IBCP) is an excellence mixed research unit (UMR 5086) administered jointly by the Conseil National de Recherche Scientifique and by Claude Bernard University of Lyon I. It is located in Lyon (France) in the Gerland area, at the confluence of the Rhone and the Saône rivers. It is one of the research units making up the Federated Research Institute (IFR 128) "Biosciences Lyon-Gerland". The current building dates from 1992 (phase 1), and was extended in 1997 (phase 2, North West wing) and again in 2003 (phase 3, two additional floors), making a current surface area of 4500 m2 distributed over 5 floors. In general, the aim of the research carried out at the IBCP is the study of proteins in their biological context. The approaches used include integrative cellular (cell culture, various types of microscopies) and molecular techniques, at both experimental (including biocrystallography and nuclear magnetic resonance) and theoretical (structural bioinformatics) levels. Research at the IBCP is organised into three main areas, bringing together 13 groups working on topics such as cancer, extracellular matrix, tissue engineering, membranes, cell transport and signalling, bioinformatics and structural biology. Altogether, it includes about 150 people (researchers, university academic staff, technicians, administrative staff, postdoctoral researchers and PhD graduates), representing 9 nationalities, of which half have tenured positions. The IBCP houses the Lyon-Gerland site of the Rhone-Alpes Bioinformatics Centre (PRABI). The Institute is equipped with all major facilities related to Protein Science at both molecular and cellular levels. Additional, more specific, equipments are available in close proximity, within the IFR 128.

DIFFERENTIATION & CELL CYCLE GROUP, ECOLE NORMALE SUPERIEURE DE LYON

Ecole Normale Supérieure de Lyon 46, allée d'Italie

69364 Lyon cedex 07 Website: www.ens-lyon.fr

Brief description of the Research Center The Ecole Normale Supérieure de Lyon is one of the top academic research institutions of France. The Laboratory of molecular and cellular Biology has state of the art facilities for world class biological research ranging from standard laboratory to microscopy, genomics and proteomics platforms to name but a few of the resources. There is a a diversity of expertise in biology, easily accessible in the open format of the laboratory but also technologies at the interface of biology, chemistry, physics and materials science, in the Joliot-Curie laboratories.

GUIDA UPG2 (versione del 16-1-06) 20Over 250 scientists in three research units – Virology, plant science, molecular and cellular biology train over 40 graduates and post-doctoral fellows at any given time, offering an ideal ratio of seasoned scientists to graduates. There is significant incentive to innovate as illustrated by the nimber of high tech start-ups that have emerged from the labs in several areas in addition to biology. IRLANDA

PR euroCHEM Ltd (CORK)

PR euroCHEM Ltd Ballyvolane Business Park, unit C

Spring Lane, Ballyvolane Cork

Website: www.preurochem.com

Brief description of the Center PR euroCHEM Ltd has State-of-the art laboratories for conducting Research and Development and fully equipped with a full analytical means such as HPLC, NMR, IR,etc.. SPAGNA

NEUROPHARMA (MADRID)

Avda. De la Industria 52, E-28760 Tres Cantos (23 Km from Madrid)

Website: www.neuropharma.es

Brief description of the Research Center NeuroPharma is a company financially supported for the chemical industry holding ZELTIA which was born in May 2000. Our mission is to research, develop and commercialise new drugs active for CNS. In this first step of our company we have created a potent R&D departament and we have focused our research to the future therapy of Alzheimer´s disease. As source of biodiversity in our assays we used extracts of marine organism as well as directed drug design programs. We have now 1.800 m2 of laboratories with basic equipment for molecular biology, cell cultures (including primary cell cultures), biochemistry, organic and bioanalytical analysis, organic synthesis and natural products isolation. We have a broad high technology equipment such NMR (400 MHz), LC-MS, LC-MS/MS, HPLC (analytical and preparative), microwave organic synthesis reactor, ELISA equipments, fluorimeters, fluorescence microscopy, scintillation counter, etc. Up to date, we are 30 researchers in staff from biology, chemistry and pharmaceutical areas. We have three main projects in different state of development each of it. In these projects we are focused on specific targets relevant for Alzheimer´s disease with the aim of finding new drugs that act as disease-modifying agents and that could interfere with the main histological hallmarks of the pathology: beta-amyloid and tau protein. We develop our own screening assays. The cell-based ones are selected if it possible for the specific target. In this moment we have a very efficient platform for primary and secondary screening in the three projects in course. That allow us to select with high efficacy candidates for further development. In the chemistry department, we have a potent research group in natural products that proceed to the bio-assay guided isolation of the positives. After chemical elucidation of the hit, two programs born in parallel: the total

GUIDA UPG2 (versione del 16-1-06) 21synthesis of the marine natural product and the medicinal chemistry programs of analogs that allow to define the pharmacophore. At the same time ADME properties are considering in this step, and further modifications to structure were done in order to obtain oral bioavailable compounds and to improve the cross of BBB. Preliminary pharmacokinetic screening is also performed in our laboratories.

Per ulteriori informazioni scientifiche rivolgersi a:

Dr. Luciano Saso Facoltà di Farmacia

Dipartimento di Fisiologia Umana e Farmacologia “Vittorio Erspamer” Universita' di Roma La Sapienza P.le Aldo Moro 5, 00185 Roma

Fax. 06-49912481 E-mail: luciano.saso@uniroma1.it